US 7,320,961 B2
Method for treating a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate
Dale J. Kempf, Libertyville, Ill. (US); Richard J. Bertz, Kenosha, Wis. (US); and Jeffrey F. Waring, Franklin, Wis. (US)
Assigned to Abbott Laboratories, Abbott Park, Ill. (US)
Filed on Mar. 18, 2004, as Appl. No. 10/802,829.
Claims priority of provisional application 60/457138, filed on Mar. 24, 2003.
Prior Publication US 2004/0242509 A1, Dec. 02, 2004
Int. Cl. A61K 31/425 (2006.01); A61K 38/00 (2006.01)
U.S. Cl. 514—19  [514/365] 11 Claims
 
1. A method for inducing UGT1A1 isoform expression for treatment of a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate comprising the step of administering to a subject an effective amount of ritonavir, wherein said elevated serum concentration of the UGT1A1 substrate is not caused by administration of atazanavir.